Intercept Drug Patent Portfolio
Intercept owns 2 orange book drugs protected by 11 US patents Given below is the list of Intercept's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10052337 | Compositions of obeticholic acid and methods of use | 26 Apr, 2036 | Active |
| US10751349 | Compositions of obeticholic acid and methods of use | 26 Apr, 2036 | Active |
| US10758549 | Compositions of obeticholic acid and methods of use | 26 Apr, 2036 | Active |
| US10047117 | Preparation and uses of obeticholic acid | 06 Sep, 2033 | Active |
| US10174073 | Preparation and uses of obeticholic acid | 17 Jun, 2033 | Active |
| US9238673 | Preparation and uses of obeticholic acid | 17 Jun, 2033 | Active |
| US9040518 | Chemical Compounds | 06 Sep, 2031 | Active |
| USRE48286 | Steroids as agonists for FXR | 21 Feb, 2027 | Active |
| US7138390 | Steroids as agonists for FXR | 16 Nov, 2022 | Expired |
| US8058267 | Steroids as agonists for FXR | 21 Feb, 2022 | Expired |
| US8377916 | Steroids as agonists for FXR | 21 Feb, 2022 | Expired |
Latest Legal Activities on Intercept's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Intercept.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent | 24 Mar, 2025 | US8377916 |
| Change in Power of Attorney (May Include Associate POA) | 20 Feb, 2025 | US10751349 |
| Email Notification | 20 Feb, 2025 | US10758549 |
| Email Notification | 20 Feb, 2025 | US10751349 |
| Change in Power of Attorney (May Include Associate POA) | 20 Feb, 2025 | US10758549 |
| Email Notification | 04 Dec, 2024 | USRE48286 |
| Email Notification | 04 Dec, 2024 | US10174073 |
| Change in Power of Attorney (May Include Associate POA) | 04 Dec, 2024 | USRE48286 |
| Change in Power of Attorney (May Include Associate POA) | 04 Dec, 2024 | US10174073 |
| Maintenance Fee Reminder Mailed | 07 Oct, 2024 | US8377916 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Mar, 2024 | US10758549 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Feb, 2024 | US10751349 |
|
Expire Patent
Critical
| 18 Dec, 2023 | US8058267 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jul, 2023 | US9238673 |
|
Maintenance Fee Reminder Mailed
Critical
| 03 Jul, 2023 | US8058267 |
Intercept's Family Patents
Intercept Drug List
Given below is the complete list of Intercept's drugs and the patents protecting them.
1. Lynavoy
Lynavoy is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9040518 | Chemical Compounds |
06 Sep, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lynavoy's drug page
2. Ocaliva
Ocaliva is protected by 10 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10052337 | Compositions of obeticholic acid and methods of use |
26 Apr, 2036
(9 years from now)
| Active |
| US10751349 | Compositions of obeticholic acid and methods of use |
26 Apr, 2036
(9 years from now)
| Active |
| US10758549 | Compositions of obeticholic acid and methods of use |
26 Apr, 2036
(9 years from now)
| Active |
| US10047117 | Preparation and uses of obeticholic acid |
06 Sep, 2033
(7 years from now)
| Active |
| US10174073 | Preparation and uses of obeticholic acid |
17 Jun, 2033
(6 years from now)
| Active |
| US9238673 | Preparation and uses of obeticholic acid |
17 Jun, 2033
(6 years from now)
| Active |
| USRE48286 | Steroids as agonists for FXR |
21 Feb, 2027
(7 months from now)
| Active |
| US7138390 | Steroids as agonists for FXR |
16 Nov, 2022
(3 years ago)
| Expired |
| US8058267 | Steroids as agonists for FXR |
21 Feb, 2022
(4 years ago)
| Expired |
| US8377916 | Steroids as agonists for FXR |
21 Feb, 2022
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ocaliva's drug page